Results 181 to 190 of about 2,182,759 (269)

Scoping review of the role of pharmacometrics in model-informed drug development. [PDF]

J Pharmacokinet Pharmacodyn
Bhat AG, Shin E, Roy A, Ramanathan M.
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Development of Group Counseling Guidelines for Student Self Control Improvement in Prevention of Drug Abuse

, 2020
Liza Fidiawati, Firman Firman, Solfema Solfema   +2 more
openalex   +2 more sources

Expediting Drug Development in Japan: A PMDA Perspective. [PDF]

Clin Pharmacol Ther
Kohno Y, Ishiguro A, Yasukawa T, Yasuda N, Tanaka D, Araki Y, Takahashi Y, Uyama Y, Fujiwara Y.   +8 more
europepmc   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

The effect of comparative effectiveness research on drug development innovation: a 360° value appraisal

, 2011
John Doyle
openalex   +2 more sources

Co-regulation of microglial subgroups in Alzheimer's amyloid pathology: Implications for diagnosis and drug development. [PDF]

PLoS One
Zhou Y, Huang Y, Fan Y, Xue F.
europepmc   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Development of drug level monitoring in the blood and liver by microdialysis method.

, 1992
Tomomitsu Kurata
openalex   +2 more sources

Exploring Artificial Intelligence's Potential to Enhance Conventional Anticancer Drug Development. [PDF]

Drug Dev Res
Bobolea SȘ, Hinoveanu MI, Dimitriu A, Brașoveanu MA, Iliescu CN, Dinu-Pîrvu CE, Ghica MV, Anuța V, Popa L, Prisada RM.   +9 more
europepmc   +1 more source